90Y Zevalin

DRUG2 trials

Sponsors

SCRI Development Innovations, LLC, Tufts Medical Center

Conditions

Multiple MyelomaNon-Hodgkins Lymphoma

Phase 2

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

CompletedNCT00193505

SCRI Development Innovations, LLCNon-Hodgkins Lymphoma

Start: 2003-10-31End: 2005-08-31Target: 40Updated: 2011-05-03

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

TerminatedNCT01207765

Tufts Medical CenterMultiple Myeloma

Start: 2008-04-30End: 2013-06-30Updated: 2017-03-20